- Push-out Score determined
- After about three years in the position
- Praise and thanks for Kenyon
- Russ Trenary taking over
- Kenyon will remain as Chief Financial Officer at Outlook Therapeutics
(exechange) — Iselin, New Jersey, July 7, 2021 — Larry Kenyon, chief executive of Outlook Therapeutics, leaves his position. As announced by Outlook Therapeutics Inc. in a news release on Wednesday, July 7, 2021, Lawrence A. (Larry) Kenyon leaves his post as chief executive officer at the biopharmaceutical company after about three years in the role.
The exact date of Larry Kenyon’s departure from his post was not explicitly stated in the announcement.
Larry Kenyon’s duties as CEO will be taken over by C.Russell (Russ) Trenary, a former President & Chief Executive Officer at InnFocus Inc.
The fact that Larry Kenyon’s successor is brought in from outside suggests that the board may seek to stimulate change with fresh ideas and new initiatives.
Outlook Therapeutics has already removed the name of Kenyon as Chief Executive Officer from the leadership page on its website and lists Russ Trenary as President & Chief Executive Officer.
“The right leadership team to develop a fully integrated ophthalmic company”
Outlook Therapeutics did not give an explicit reason for Larry Kenyon’s departure from the CEO post. Randy Thurman, Executive Chairman of the Outlook Therapeutics Board of Directors, said: “With the addition of Russ, we have the right leadership team to develop a fully integrated ophthalmic company.”
Kenyon will remain as CFO at Outlook Therapeutics
“Lawrence A. Kenyon, who has served as Outlook Therapeutics’ President, CEO and CFO since June 2018, will continue serving as CFO and as a member of the Board of Directors,” Outlook Therapeutics said.
Share price decline since July 2018
The announcement follows a decline in Outlook Therapeutics Inc.’s share price of 65% since July 2018.
Chaired by Randy Thurman
Randy Thurman serves as Outlook Therapeutics Inc.’s Executive Chairman.
Thurman has served as the Executive Chairman of the Company’s board of directors since June 2018 and served as a member of the Company’s board since April 2018.
In the position of CEO since 2018
Larry Kenyon became CEO of the Company in 2018.
Kenyon has served as a member of the Company’s board of directors, Chief Executive Officer and President since August 2018, as Interim Chief Executive Officer from June 2018 to August 2018, and as the Company’s Chief Financial Officer, Treasurer and Corporate Secretary since September 2015.
Prior to that, from February 2014 to September 2015, Kenyon served as the Chief Financial Officer of Arno Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics for cancer and other life-threatening diseases, and also as Chief Operating Officer from July 2014 to September 2015.
From December 2011 to March 2013, Kenyon served as the Interim President & Chief Executive Officer, Chief Financial Officer and Secretary of Tamir Biotechnology, Inc., a publicly held biopharmaceutical company engaged in the development of oncology and anti-infective therapeutics.
Prior to that, from December 2008 to July 2010, Kenyon was the Executive Vice President, Finance and, commencing in March 2009, the Chief Financial Officer of, Par Pharmaceutical Companies, Inc., a publicly held generic and branded specialty pharmaceutical company, or Par.
Prior to joining Par, Kenyon was the Chief Financial Officer and Secretary of Alfacell Corporation, or Alfacell, from January 2007 through February 2009 and also served at various times during this period as Alfacell’s Executive Vice President, Chief Operating Officer and President, and was a member of Alfacell’s board of directors from November 2007 to April 2009.
Prior to joining Alfacell, Kenyon served as the Executive Vice President, Chief Financial Officer and Corporate Secretary at NeoPharm, Inc., a publicly traded biopharmaceutical company, from 2000 to 2006.
Kenyon received a B.A. in Accounting from the University of Wisconsin — Whitewater and is a CPA in Illinois.
Push-out Score determined
The Push-out Score™ determined by exechange gauges the pressure surrounding Larry Kenyon’s move on a scale of 0 to 10.
exechange reached out to Outlook Therapeutics and offered the company the opportunity to comment on the score.
Read the full story in the exechange report 28.2021 ($).